Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.91, indicating a -6.19% shift from the previous trading day.

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

Recursion can validate hypotheses and design compounds much more quickly than drugmakers using traditional methods. And its cost to get to the point of filing an Investigational New Drug (IND) ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...

It's tough to get excited about buying most growth stocks right now. Too many of them are just too expensive relative to the risk they bring to the table. Not all of them, though.

If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

Discover how Zero Knowledge Proof (ZKP) unlocks infinite scalability through recursive proofs. Join the whitelist soon to pre ...

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

It may sound counterintuitive to use AI to prepare for AI, but this recursive strategy is what enables scalable success. When ...